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VALVE SURGERY: RESULTS OF




We read with great interest the
recent publication by Santana and
colleagues,1 entitled ‘‘Staged Percuta-
neous Coronary Intervention and Min-
imally Invasive Valve Surgery: Results
of a Hybrid Approach to Concomitant
Coronary and Valvular Disease.’’ A to-
tal of 65patientswhounderwent staged
percutaneous coronary intervention
andminimally invasive cardiac surgery
(MICS) valve surgery were compared
with 51 patients who underwent com-
bined valve/coronary artery bypass
grafting. The authors are to be congrat-
ulated for their excellent short-term1684 The Journal of Thoracic andresults in the MICS group, particularly
the lack of mortality. However, draw-
ing conclusions between the 2 groups
is problematic in that there were 6 dif-
ferent surgeons in the control group
versus 1 surgeon in the MICS group.
It iswell known thatmortality andmor-
bidity rates in valve surgery are highly
correlated to the caseload of the indi-
vidual surgeon.2 We would question if
the 28% versus 1.5% cumulative inci-
dence of adverse short-term outcomes,
including death, stroke, and renal fail-
ure, in the control versus the experi-
mental group is merely a reflection of
this fact.
Another concern is 61 of 65 patients
in the hybrid group had percutaneous
coronary intervention of the left anterior
descending artery before MICS, and
only 55.5% of the stentswere drug elut-
ing. In view of the the well-documented
durability of the left internal thoracic ar-
tery to the left anterior descending ar-
tery, with both its salutary impact on
longevity and major adverse cardiac
outcomes, are these patients possibly
being shortchanged in the zeal to per-
form MICS?
We also noted that in the MICS mi-
tral cohort, there was only a 58% re-
pair rate (14/24) despite no mention
of rheumatic causes. Other than 6 cal-
cific mitral valves, it seems plausible
that the repair rate should have been
higher in the hands of such a high-
volume surgeon. Again, perhaps the
lack of adequate exposure inherent to
a ‘‘4- to 5-cm’’ MICS incision com-
promised the ability to attain a satis-
factory repair.
Finally, nowhere in the article was
there any mention of atrial fibrillation
(AF). It is unlikely that none of these
patients would have any preoperative
history of such. Ad and colleagues3
recently reported that only 40.6% of
patients with a history of AF have it
addressed at the time of concomitant
heart surgery. Knowing the favorable
effects of a concomitant Cox-maze
on ejection fraction, stroke, and life
span, as well as the fact that this pro-
cedure can be applied via a MICSCardiovascular Surgery c June 2013approach, the authors should recon-
sider their strategy in those patients
with a significant history of AF.
We applaud this and other efforts to
make cardiac surgery less invasive.
However, suboptimal mitral repair
rates and infrequent use of the left
internal thoracic artery, as well as
overlooking preoperative AF, may
significantly compromise long-term
patient outcomes.
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OF THE SAME COIN?
To the Editor:
Jakobsen and colleagues1 are to
be congratulated for pursuing alterna-
tives to supranormal potassium cardio-
plegia in cardiac surgery. Since
a 15-year moratorium was placed on
Melrose’s hyperkalemic solution in the
late 1950s, investigators in cardiopro-
tection have attempted to find a method
Letters to the Editorto achieve polarized arrest that reduces
(1) Naþ and Ca2þ loading, (2) vasocon-
striction, (3) endothelial dysfunction,
(4) reperfusion arrhythmias, and (5)
contractile stunning.2 In the 1990s,
adenosine triphosphate–sensitive Kþ
channel openers provided initial hope
for amethod to induce polarized arrest3;
however, severe post-arrest arrhythmias
thwarted clinical adoption.
The clinical study by Jakobsen and
colleagues1 tested the hypothesis that
cold 1.2 mmol/L adenosine crystalloid
cardioplegia can achieve polarized ar-
rest and provide superior cardioprotec-
tion compared with a 20 mmol/L
hyperkalemic solution in low-risk pa-
tients. Their study found that adenosine
cardioplegia arrested the heart faster, re-
duced the incidence of atrial fibrillation
by more than 50%, and was associated
with lower postoperative plasma Kþ
levels. There were no differences in
postoperative troponin T, creatine
kinase-MB, creatinine, hemodynamics,
cardiac index, or endothelial activation.1
Adenosine has been investigated as
a potential cardioprotective agent in
cardiac surgery during the past several
decades. In 1989, Schubert and col-
leagues4 were the first to show that 10
mmol/L of adenosine rapidly arrested
the heart. However, persistent atrioven-
tricular block4 precluded its further de-
velopment as a polarizing arresting
agent, and it became an adjunct to
supranormal potassium.5 During the
past 20 years, the benefits of adjunctive
adenosine (<2mmol/L) in cardioplegia
have been mixed, ranging frommodest
effects5 to no benefits at all.6 The proto-
col reported by Jakobsen and col-
leagues1 used 1.2 mmol/L adenosine
to achieve polarized arrest. However,
this concentration is approximately
one tenth that used in earlier studies
in which adenosine was the primary ar-
resting agent.4 This discrepancy raises
an important question ofwhether aden-
osine is really the sole arresting agent in
Jakobsen’s study.
In 2004, Dobson and Jones7 re-
ported that adenosine (0.2 mmol/L)
and lidocaine (0.5 mmol/L) (AL) inThe Journala modified Krebs–Henseleit solution
arrested the heart in a polarized state,
with significantly improved func-
tional recoveries compared with St
Thomas’ solution. Although both
lidocaine and procaine are Naþ fast-
channel blockers, lidocaine was cho-
sen in AL cardioplegia because as
a class 1B antiarrhythmic, it shortens
repolarization time, whereas procaine
(class 1A) prolongs repolarization
time, which may cause postoperative
reanimation irritability. The AL con-
cept of polarized arrest was subse-
quently confirmed in the canine
model of cardiopulmonary bypass.8
Therefore, the efficacy of adenosine
cardioplegia in the study by Jakobsen
and colleagues1 could be due to its
combination with procaine. Whether
adenosine acted alone or not is impor-
tantbecause future studies testing aden-
osine as theprimaryarresting agentwill
derive their impetus from studies such
as the one by Jakobsen and colleagues.1
Precedence has been set for a polarized
alternative using adenosine and local
anesthetic (eg, lidocaine), which is the
proprietary composition ofHibernation
Therapeutics Global, Inc (Wicklow,
Ireland) and is trademarked and avail-
able asAdenocaine in theUnited States
from Central Admixture Pharmacy
Services (Kent, Wash). A recent pro-
spective randomized trial in Verona,
Italy, showed superiority of an AL car-
dioplegic formulation in high-risk pa-
tients compared with a 4:1 Buckberg
solution9; further clinical confirmation
for use ofALas a primary arresting for-
mulation that extends the data of Cor-
vera and colleagues8 is forthcoming.
The good news is that these studies col-
lectively give hope that an alternative to
supranormal potassium cardioplegia is
on the horizon for the good of low-
and high-risk pediatric and adult pa-
tients alike.
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j.jtcvs.2013.01.049Reply to the Editor:
We greatly appreciate the interest
by Drs Vinten Johansen and Dobson
in our article showing the efficacy
and beneficial impact of adenosine in-
stead of hyperkalemia in cold crystal-
loid cardioplegia. Their comments
raise interesting and relevant questions
regarding adenosine in cardioplegiay c Volume 145, Number 6 1685
